02126 JW THERAP-B
- 1.290
- -0.010-0.77%
JW THERAP-B News
Pharmaceutical Junuo (02126.HK): Benoda commercialization is successful, and the application space is expected to continue to expand
Pharmaceutical Junuo (02126.HK): Significant results in cost reduction and efficiency explore clinical applications of self-exemption
Medication Minjuno-B (2126.HK): Benodar's high number of prescriptions increased and gross margin improved significantly
Pharmaceutical MingJunuo-B (02126.HK): Sales increased 373%, gross margin increased to 40%
Medication Minjuno-B (02126.HK): Further exploration of solid tumors returned to JWATM214 patients
Changes in Hong Kong stocks | Pharmaceutical Ming Junuo-B (02126) fell nearly 6% due to low penetration and pressure on future average prices of CAR-T products, UBS drastically lowered target prices
Pharmaceutical Ming Junuo B (02126.HK): Pharmaceutical Ming Junuo Interim Report Performance Review
Pharmaceutical Ming Junuo-B (02126.HK): China's CAR-T, which has a high starting point for internationalization, is setting sail for the first Class 1 drug
Pharmaceutical Mingjunuo (2126.HK) Annual Report Review: Commercialization and payment system construction are progressing smoothly and continuing to expand R&D pipelines
Pharmaceutical MingJunuo (02126.HK): RELMA-CEL Approved for Listing Begins a New Stage of Commercialization
Medica Minjunuo (02126.HK): Leading integrated cell therapy platform company
Guotai Junan International: Medication Juno-B (02126) Relma-cel has significant safety advantages and is expected to be the best CAR-T treatment in its class
Pharmaceutical Mingju-B (2126.HK): An emerging pharmaceutical company that focuses on cellular immunotherapy giants
Pharmaceutical Mingjunuo (Cayman) Limited (02126.HK) Rating: IPO Report
Medication Junuo B (02126.HK)
New share Newsletter: Yao Ming Juno (Cayman) Co., Ltd.-B (02126.HK))
No Data
